Physician profile
Anastasios Tsiolakis
NPI 1225430705
$4,116.76
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,883 · 2022: $2,107 · 2023: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $127.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $560.60 | 2021-2023 | |
| Lilly USA, LLC | $538.37 | 2021-2022 | |
| Novo Nordisk INC | $345.62 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $308.19 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $204.75 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.79 | 2021-2022 | |
| Glaxosmithkline, LLC. | $197.73 | 2021-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $196.28 | 2021-2023 | |
| Amarin Pharma, INC. | $183.30 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $115.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $111.93 | 2022 | |
| Astellas Pharma US INC | $106.68 | 2021-2022 | |
| Optinose US, INC. | $100.42 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $85.91 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $82.78 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $82.29 | 2021-2023 | Airduo Digihaler |
| Bayer Healthcare Pharmaceuticals INC. | $75.61 | 2022-2023 | |
| Grifols USA, LLC | $65.78 | 2021 | |
| Esperion Therapeutics, INC. | $61.90 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $52.21 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $48.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $48.81 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.45 | 2021 | |
| Sunovion Pharmaceuticals INC. | $47.14 | 2022 | |
| Bausch Health US, LLC | $37.09 | 2021 | |
| Currax Pharmaceuticals LLC | $32.63 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.49 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.02 | 2022 | |
| Allergan, INC. | $26.55 | 2021 | |
| Corcept Therapeutics | $24.84 | 2022 | |
| Corium, LLC | $20.58 | 2022 | |
| Zealand Pharma US, INC. | $17.03 | 2022 | |
| Eisai INC. | $16.74 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anastasios Tsiolakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.